Clinical outcomes of patients with remitting ulcerative colitis after discontinuation of indigo naturalis.

Discontinuation Indigo naturalis Relapse Ulcerative colitis

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 Mar 2024
Historique:
received: 19 12 2023
accepted: 07 03 2024
medline: 9 3 2024
pubmed: 9 3 2024
entrez: 8 3 2024
Statut: epublish

Résumé

Indigo naturalis is an effective treatment for ulcerative colitis. However, long-term use of indigo naturalis causes adverse events, such as pulmonary hypertension. The natural history of patients with ulcerative colitis who discontinued indigo naturalis after induction therapy is unknown. Moreover, the clinical features of patients who relapsed within 52 weeks after the discontinuation of indigo naturalis are unclear. This study aimed to assess the clinical outcomes of patients with ulcerative colitis after discontinuation of indigo naturalis and to identify potential markers responsible for relapse. This single-center retrospective study investigated the follow-up of 72 patients who achieved a clinical response 8 weeks after indigo naturalis treatment. We observed relapse in patients with ulcerative colitis after the discontinuation of indigo naturalis. We analyzed the factors predicting long-term outcomes after discontinuation of indigo naturalis. Relapse was observed in 24%, 57%, and 71% of patients at 8, 26, and 52 weeks, respectively. There were no predictive markers in patients who relapsed within 52 weeks after the discontinuation of indigo naturalis. The ulcerative colitis relapse rate after indigo naturalis discontinuation was high. Follow-up treatment is required after the discontinuation of indigo naturalis in patients with ulcerative colitis.

Identifiants

DOI: 10.1038/s41598-024-56543-y PMID: 38459203
pubmed: 38459203
doi: 10.1038/s41598-024-56543-y
pii: 10.1038/s41598-024-56543-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5778

Subventions

Organisme : Japanese Society for the Promotion of Science (JSPS)
ID : 17K19668
Organisme : Japanese Society for the Promotion of Science (JSPS)
ID : 21H02905
Organisme : Japanese Society for the Promotion of Science (JSPS)
ID : 20H00536
Organisme : JST forest
ID : 21457195
Organisme : Japan Agency for Medical Research and Development
ID : 19ek0109214
Organisme : Japan Agency for Medical Research and Development
ID : 21gm1510002h0001

Informations de copyright

© 2024. The Author(s).

Références

Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L. & Colombel, J. F. Ulcerative colitis. Lancet (London, England) 389(10080), 1756–1770 (2017).
doi: 10.1016/S0140-6736(16)32126-2 pubmed: 27914657
Turner, D., Walsh, C. M., Steinhart, A. H. & Griffiths, A. M. Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 5(1), 103–110 (2007).
doi: 10.1016/j.cgh.2006.09.033 pubmed: 17142106
Ogata, H. et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm. Bowel Dis. 18(5), 803–808 (2012).
doi: 10.1002/ibd.21853 pubmed: 21887732
Sandborn, W. J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1), 85–95 (2014).
doi: 10.1053/j.gastro.2013.05.048 pubmed: 23735746
Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265 (2012).
doi: 10.1053/j.gastro.2011.10.032 pubmed: 22062358
Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 60(6), 780–787 (2011).
doi: 10.1136/gut.2010.221127 pubmed: 21209123
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005).
doi: 10.1056/NEJMoa050516 pubmed: 16339095
Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381(13), 1201–1214 (2019).
doi: 10.1056/NEJMoa1900750 pubmed: 31553833
Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376(18), 1723–1736 (2017).
doi: 10.1056/NEJMoa1606910 pubmed: 28467869
Feagan, B. G. et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet (London, England) 397(10292), 2372–2384 (2021).
doi: 10.1016/S0140-6736(21)00666-8 pubmed: 34090625
Sandborn, W. J. et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 158(8), 2139-2149.e2114 (2020).
doi: 10.1053/j.gastro.2020.02.030 pubmed: 32092309
Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369(8), 699–710 (2013).
doi: 10.1056/NEJMoa1215734 pubmed: 23964932
Matsuoka, K. et al. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol. Hepatol. 7(7), 648–657 (2022).
doi: 10.1016/S2468-1253(22)00022-X pubmed: 35366419
Suzuki, H. et al. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World J. Gastroenterol. 19(17), 2718–2722 (2013).
doi: 10.3748/wjg.v19.i17.2718 pubmed: 23674882 pmcid: 3645393
Fukunaga, K. et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J. Gastroenterol. Hepatol. 27(12), 1808–1815 (2012).
doi: 10.1111/j.1440-1746.2012.07215.x pubmed: 22775479
Naganuma, M. et al. Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis. Gastroenterology 154(4), 935–947 (2018).
doi: 10.1053/j.gastro.2017.11.024 pubmed: 29174928
Naganuma, M. et al. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: A post hoc analysis from the INDIGO study. J. Gastroenterol. 55(2), 169–180 (2020).
doi: 10.1007/s00535-019-01625-2 pubmed: 31529220
Kawai, S. et al. Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation. J. Gastroenterol. 52(8), 904–919 (2017).
doi: 10.1007/s00535-016-1292-z pubmed: 27900483
Sugimoto, S., Naganuma, M. & Kanai, T. Indole compounds may be promising medicines for ulcerative colitis. J. Gastroenterol. 51(9), 853–861 (2016).
doi: 10.1007/s00535-016-1220-2 pubmed: 27160749
Metidji, A. et al. The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity. Immunity 49(2), 353-362.e355 (2018).
doi: 10.1016/j.immuni.2018.07.010 pubmed: 30119997 pmcid: 6104739
Yoshimatsu, Y. et al. Aryl hydrocarbon receptor signals in epithelial cells govern the recruitment and location of Helios(+) Tregs in the gut. Cell Rep. 39(6), 110773 (2022).
doi: 10.1016/j.celrep.2022.110773 pubmed: 35545035
Naganuma, M. et al. Adverse events in patients with ulcerative colitis treated with indigo naturalis: A Japanese nationwide survey. J. Gastroenterol. 54(10), 891–896 (2019).
doi: 10.1007/s00535-019-01591-9 pubmed: 31102012
Hiraide, T. et al. Pulmonary arterial hypertension caused by AhR signal activation protecting against colitis. Am. J. Respir. Crit. Care Med. 203(3), 385–388 (2021).
doi: 10.1164/rccm.202009-3385LE pubmed: 33052717
Hu, A. et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin. Gastroenterol. Hepatol. 19(7), 1366-1376.e1362 (2021).
doi: 10.1016/j.cgh.2020.07.012 pubmed: 32668338
Masaki, T. et al. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc. Natl. Acad. Sci. USA 118(11), 1 (2021).
doi: 10.1073/pnas.2023899118
Nishio, M., Hirooka, K. & Doi, Y. Pulmonary arterial hypertension associated with the Chinese herb indigo naturalis for ulcerative colitis: It may be reversible. Gastroenterology 155(2), 577–578 (2018).
doi: 10.1053/j.gastro.2018.04.038 pubmed: 30001991

Auteurs

Fumie Shimada (F)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
ORCID: 0009-0008-9980-643X

Yusuke Yoshimatsu (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
ORCID: 0000-0003-0735-5499

Tomohisa Sujino (T)

Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. tsujino1224@keio.jp.
ORCID: 0000-0003-0699-6577

Tomohiro Fukuda (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Division of Gastroenterology, Yokohama Municipal Citizen's Hospital, 1-1, Nishimachi, Mitsuzawa, Kanagawaku, Yokohama, Kanagawa, 221-0855, Japan.

Yasuhiro Aoki (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yukie Hayashi (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Anna Tojo (A)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Takaaki Kawaguchi (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Hiroki Kiyohara (H)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Shinya Sugimoto (S)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Kosaku Nanki (K)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yohei Mikami (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Kentaro Miyamoto (K)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Miyarisan Pharmaceutical Co., Ltd., 1-10-3, Kaminakazato, Kita-ku, Tokyo, 114-0016, Japan.

Kaoru Takabayashi (K)

Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Naoki Hosoe (N)

Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Motohiko Kato (M)

Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Haruhiko Ogata (H)

Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Makoto Naganuma (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Department of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1, Shinmachi, Maikatashi, Osaka, 573-1191, Japan.

Takanori Kanai (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. takagast@keio.jp.
ORCID: 0000-0002-1466-4532

Classifications MeSH